Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulation
Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.
1. A primary cell comprising:
(a) a modified single guide RNA (sgRNA) comprising a first nucleotide sequence that is complementary to a target nucleic acid within the primary cell and a second nucleotide sequence that interacts with a CRISPR-associated protein (Cas) polypeptide, wherein:
(i) about 10% to about 30% of nucleotides in the first nucleotide sequence and/or about 1% to about 10% of nucleotides in the second nucleotide sequence are modified nucleotides;
(ii) the modified sgRNA comprises a modified nucleotide within five nucleotides from the 5′ end of the first nucleotide sequence and/or within five nucleotides from the 3′ end of the second nucleotide sequence; and
(iii) the modified nucleotides are selected from the group consisting of a 2′-O-methyl 3′-phosphorothioate (MS) nucleotide, a 2′-O-methyl 3′-thioPACE (MSP) nucleotide, and a combination thereof; and
(b) a Cas polypeptide, an mRNA encoding the Cas polypeptide, or a recombinant expression vector comprising a nucleotide sequence encoding the Cas polypeptide,
wherein the modified sgRNA guides the Cas polypeptide to the target nucleic acid, and wherein the modified sgRNA induces a gene regulation of the target nucleic acid with an enhanced activity relative to a corresponding unmodified sgRNA.
2. The primary cell of claim 1 , wherein the enhanced activity comprises increased stability of the modified sgRNA and/or increased specificity of the modified sgRNA for the target nucleic acid.
3. The primary cell of claim 1 , wherein the target nucleic acid comprises a target DNA or a target RNA.
4. The primary cell of claim 3 , wherein the gene regulation comprises genome editing of the target DNA.
5. The primary cell of claim 4 , wherein the genome editing comprises homologous-directed repair (HDR) or nonhomologous end joining (NHEJ) of the target DNA.
6. The primary cell of claim 4 , further comprising a recombinant donor repair template.
7. The primary cell of claim 6 , wherein the recombinant donor repair template comprises two nucleotide sequences comprising two non-overlapping, homologous portions, wherein one of the two homologous portions is located at the 5′ e n d and the other homologous portion is located at the 3′ end of the recombinant donor template, wherein each homologous portion is homologous to a corresponding region of the target DNA to undergo genome editing.
8. The primary cell of claim 6 , wherein the recombinant donor repair template comprises a synthetic single-stranded oligodeoxynucleotide (ssODN) template comprising a nucleotide sequence encoding a mutation to correct a single nucleotide polymorphism (SNP) and two nucleotide sequences comprising two non-overlapping, homologous portions that are homologous to corresponding regions of the target DNA, wherein one of the two homologous portions is located at the 5′ e n d and the other homologous portion is located at the 3′ end of the recombinant donor template.
9. The primary cell of claim 3 , wherein the Cas polypeptide is endonuclease-deficient.
10. The primary cell of claim 1 , wherein the primary cell is isolated from a multicellular organism.
11. The primary cell of claim 10 , wherein the multicellular organism is a plant, a multicellular protist, a multicellular fungus, or an animal.
12. The primary cell of claim 1 , wherein the primary cell is a stem cell or an immune cell.
13. The primary cell of claim 12 , wherein the stem cell is a hematopoietic stem and progenitor cell (HSPC), a mesenchymal stem cell, a neural stem cell, or an organ stem cell.
14. The primary cell of claim 12 , wherein the immune cell is a T cell, a natural killer cell, a monocyte, a peripheral blood mononuclear cell (PBMC), or a peripheral blood lymphocyte (PBL).
15. A population of primary cells comprising the primary cell of claim 1 .
16. The population of primary cells of claim 15 , wherein the modified sgRNA induces the gene regulation of the target nucleic acid in at least about 30% of the population of primary cells.
17. The primary cell of claim 1 , wherein the first nucleotide sequence is about 20 nucleotides in length.
18. The primary cell of claim 1 , wherein at least two nucleotides in the first nucleotide sequence are modified nucleotides.
19. The primary cell of claim 1 , wherein one or more modified nucleotides are located within five nucleotides from the 5′-end of the first nucleotide sequence.
20. The primary cell of claim 1 , wherein from about 10% to about 30% of the nucleotides in the first nucleotide sequence are modified nucleotides.
21. The primary cell of claim 1 , wherein the second nucleotide sequence is about 80 nucleotides in length.
22. The primary cell of claim 1 , wherein at least two nucleotides in the second nucleotide sequence are modified nucleotides.
23. The primary cell of claim 1 , wherein one or more modified nucleotides are located within five nucleotides from the 3′-end of the second nucleotide sequence.
24. The primary cell of claim 1 , wherein from about 1% to about 10% of the nucleotides in the second nucleotide sequence are modified nucleotides.
25. The primary cell of claim 1 , wherein the modified sgRNA comprises one, two, or three consecutive or non-consecutive modified nucleotides at or near the 5′-end of the first nucleotide sequence and one, two, or three consecutive or non-consecutive modified nucleotides at or near the 3′-end of the second nucleotide sequence.
26. The primary cell of claim 25 , wherein the modified sgRNA comprises three consecutive modified nucleotides at the 5′-end of the first nucleotide sequence and three consecutive modified nucleotides at the 3′-end of the second nucleotide sequence.
27. The primary cell of claim 1 , wherein the primary cell comprises mRNA encoding the Cas polypeptide.
28. The primary cell of claim 1 , wherein the Cas polypeptide is a Cas9 polypeptide, a variant thereof, or a fragment thereof.
29. The primary cell of claim 1 , wherein the Cas polypeptide is a nickase.
30. A primary cell comprising:
(a) a modified single guide RNA (sgRNA) comprising a first nucleotide sequence that is complementary to a target nucleic acid within the primary cell and a second nucleotide sequence that interacts with a CRISPR-associated protein (Cas) polypeptide, wherein:
(i) about 10% to about 30% of nucleotides in the first nucleotide sequence and/or about 1% to about 10% of nucleotides in the second nucleotide sequence are modified nucleotides;
(ii) the modified sgRNA comprises a modified nucleotide within five nucleotides from the 5′ end of the first nucleotide sequence and/or within five nucleotides from the 3′ end of the second nucleotide sequence; and
(iii) the modified nucleotides are selected from the group consisting of a 2′-O-methyl 3′-phosphorothioate (MS) nucleotide, a 2′-O-methyl 3′-thioPACE (MSP) nucleotide, and a combination thereof; and
(b) a Cas polypeptide,
wherein the modified sgRNA and the Cas polypeptide are formed in a ribonucleoprotein (RNP) complex,
wherein the modified sgRNA guides the Cas polypeptide to the target nucleic acid, and wherein the modified sgRNA induces a gene regulation of the target nucleic acid with an enhanced activity relative to a corresponding unmodified sgRNA.